
Dr. Sonya Reid introduces the program by outlining the objectives of the discussion, which focus on the expanding role of genomic testing in the management of early-stage HR-positive, HER2-negative breast cancer.

Dr. Sonya Reid introduces the program by outlining the objectives of the discussion, which focus on the expanding role of genomic testing in the management of early-stage HR-positive, HER2-negative breast cancer.